Management of chronic hepatitis B

Hatef Massoumi, Paul Martin, Hui Hui Tan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Chronic hepatitis B continues to be a major global health burden. It accounts for a substantial impact on health care resources and finances in many parts of the world including Europe. Natural history and disease spectrum are varied, depending on when and how the infection is acquired. The chronic infective state increases patients' risk of progression to liver cirrhosis or hepatocellular carcinoma. Several treatment options are currently available, but their use depends on the stage of the patient's infection, which is influenced by both host and viral factors. The ultimate goals in hepatitis B treatment are to prevent disease progression, hepatic decompensation, hepatocellular carcinoma, and death. Patients with decompensated liver cirrhosis should be referred to specialized transplant centers in a timely manner.

Original languageEnglish
Pages (from-to)642-650
Number of pages9
JournalEuropean Journal of Gastroenterology and Hepatology
Volume23
Issue number8
DOIs
StatePublished - Aug 1 2011

Fingerprint

Chronic Hepatitis B
Liver Cirrhosis
Hepatocellular Carcinoma
Health Resources
Infection
Natural History
Hepatitis B
Disease Progression
Delivery of Health Care
Transplants
Liver
Therapeutics

Keywords

  • antiviral therapy
  • cirrhosis
  • hepatitis B
  • hepatocellular cancer

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Management of chronic hepatitis B. / Massoumi, Hatef; Martin, Paul; Tan, Hui Hui.

In: European Journal of Gastroenterology and Hepatology, Vol. 23, No. 8, 01.08.2011, p. 642-650.

Research output: Contribution to journalArticle

Massoumi, Hatef ; Martin, Paul ; Tan, Hui Hui. / Management of chronic hepatitis B. In: European Journal of Gastroenterology and Hepatology. 2011 ; Vol. 23, No. 8. pp. 642-650.
@article{6ce7338a63b5457b89312e4f01f5d912,
title = "Management of chronic hepatitis B",
abstract = "Chronic hepatitis B continues to be a major global health burden. It accounts for a substantial impact on health care resources and finances in many parts of the world including Europe. Natural history and disease spectrum are varied, depending on when and how the infection is acquired. The chronic infective state increases patients' risk of progression to liver cirrhosis or hepatocellular carcinoma. Several treatment options are currently available, but their use depends on the stage of the patient's infection, which is influenced by both host and viral factors. The ultimate goals in hepatitis B treatment are to prevent disease progression, hepatic decompensation, hepatocellular carcinoma, and death. Patients with decompensated liver cirrhosis should be referred to specialized transplant centers in a timely manner.",
keywords = "antiviral therapy, cirrhosis, hepatitis B, hepatocellular cancer",
author = "Hatef Massoumi and Paul Martin and Tan, {Hui Hui}",
year = "2011",
month = "8",
day = "1",
doi = "10.1097/MEG.0b013e3283474add",
language = "English",
volume = "23",
pages = "642--650",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Management of chronic hepatitis B

AU - Massoumi, Hatef

AU - Martin, Paul

AU - Tan, Hui Hui

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Chronic hepatitis B continues to be a major global health burden. It accounts for a substantial impact on health care resources and finances in many parts of the world including Europe. Natural history and disease spectrum are varied, depending on when and how the infection is acquired. The chronic infective state increases patients' risk of progression to liver cirrhosis or hepatocellular carcinoma. Several treatment options are currently available, but their use depends on the stage of the patient's infection, which is influenced by both host and viral factors. The ultimate goals in hepatitis B treatment are to prevent disease progression, hepatic decompensation, hepatocellular carcinoma, and death. Patients with decompensated liver cirrhosis should be referred to specialized transplant centers in a timely manner.

AB - Chronic hepatitis B continues to be a major global health burden. It accounts for a substantial impact on health care resources and finances in many parts of the world including Europe. Natural history and disease spectrum are varied, depending on when and how the infection is acquired. The chronic infective state increases patients' risk of progression to liver cirrhosis or hepatocellular carcinoma. Several treatment options are currently available, but their use depends on the stage of the patient's infection, which is influenced by both host and viral factors. The ultimate goals in hepatitis B treatment are to prevent disease progression, hepatic decompensation, hepatocellular carcinoma, and death. Patients with decompensated liver cirrhosis should be referred to specialized transplant centers in a timely manner.

KW - antiviral therapy

KW - cirrhosis

KW - hepatitis B

KW - hepatocellular cancer

UR - http://www.scopus.com/inward/record.url?scp=79960698828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960698828&partnerID=8YFLogxK

U2 - 10.1097/MEG.0b013e3283474add

DO - 10.1097/MEG.0b013e3283474add

M3 - Article

C2 - 21602690

AN - SCOPUS:79960698828

VL - 23

SP - 642

EP - 650

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 8

ER -